« Back
Home /
Laduviglusib (monohydrochloride)

Laduviglusib (monohydrochloride)

Item no.	HY-10182A-100mg
Manufacturer	MedChem Express
CASRN	1797989-42-4
Amount	100 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.93
Formula	C22H19Cl3N8
Citations	Poult Sci. 8 March 2022, 101825.<br/> Biochemistry and Cell Biology. Rice University. 2019 May.<br/>ACS Chem Neurosci. 2018 Dec 19;9(12):3175-3185. <br/>Acta Pharm Sin B. 2024 Apr 24.<br/>Adv Sci (Weinh). 2022 Sep;9(26):e2202505.<br/>Adv Sci (Weinh). 2024 Jan 9:e2305992.<br/>Am J Physiol Cell Physiol. 2023 May 1.<br/>Animals (Basel). 2024 May 4;14(9):1382.<br/>Ann Hematol. 2023 Sep 9.<br/>Antioxidants (Basel). 2022 Jan 29;11(2):274.<br/>Antiviral Res. 2024 Apr 20:226:105891.<br/>Biochem Biophys Res Commun. 2018 Sep 5;503(2):1123-1129.<br/>Biochem Biophys Res Commun. 2020 Apr 2;524(2):280-287.<br/>Biochem Biophys Res Commun. 29 December 2021.<br/>Bioengineering (Basel). 2023 Jun 9, 10(6), 702.<br/>Biomaterials. 2018 Oct;180:12-23.<br/>Biomaterials. 2018 Dec 6;193:30-46.<br/>bioRxiv. 2023 Aug 14.<br/>bioRxiv. 2023 Jun 28.<br/>bioRxiv. 2024 Feb 2.<br/>bioRxiv. 2024 Mar 1.<br/>bioRxiv. 2024 Mar 12.<br/>bioRxiv. 2024 Mar 14.<br/>Cancer Biol Med. 2020 Aug 15;17(3):707-725.<br/>Cancer Lett. 2024 Jun.<br/>Cancers (Basel). 2021 Mar 3;13(5):1079.<br/>Cell Biol Int. 2022 Sep 18.<br/>Cell Death Differ. 2020 Jul;27(7):2158-2175. <br/>Cell Death Dis. 2020 Mar 30;11(3):206.<br/>Cell Death Dis. 2022 Mar 30;13(3):284.<br/>Cell Death Discov. 2021 Oct 2;7(1):271.<br/>Cell Death Discov. 2024 Mar 9;10(1):123.<br/>Cell Discov. 2023 Jun 6;9(1):53.<br/>Cell Metab. 2024 Jun 18:S1550-4131(24)00189-X.<br/>Cell Prolif. 2021 Jan;54(1):e12932.<br/>Cell Prolif. 2022 Mar 11;e13209.<br/>Cell Prolif. 2023 May 5;e13498.<br/>Cell Prolif. 2024 Jan 12:e13599.<br/>Cell Regen. 2020 Sep 3;9(1):15.<br/>Cell Rep Med. 2020 Dec 22;1(9):100161.<br/>Cell Rep Med. 2024 Apr 16:101520.<br/>Cell Rep. 2021 Nov 2;37(5):109949.<br/>Cell Rep. 2022 Mar 29;38(13):110570.<br/>Cell Reprogram. 2017 Dec;19(6):363-371.<br/>Cell Signal. 2016 Mar;28(3):148-56. <br/>Cell Signal. 2022 Nov 17;110526.<br/>Cell Stem Cell. 2022 Jul 7;29(7):1102-1118.e8.<br/>Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9.<br/>Cells & Development. 2021, 203665.<br/>Chem Eng J. 1 January 2023, 138737.<br/>Chemosphere. 2018 Oct 23;216:372-378. <br/>Commun Biol. 2024 Apr 29;7(1):510.<br/>Curr Biol. 2020 Nov 2;30(21):4128-4141.e5.<br/>Curr Protoc Cell Biol. 2018 Dec;81(1):e62.<br/>Curr Res Neurobiol. 2023 Jun 17, 100095.<br/>EMBO Rep. 2023 Jul 4;e57499.<br/>Environ Toxicol. 2017 Oct;32(10):2316-2322.<br/>Eur J Pharm Sci. 2021 Sep 10;106003.<br/>Exp Cell Res. 2022 Nov 11;422(1):113416.<br/>Exp Ther Med. 2020 Mar;19(3):1701-1710.<br/>FASEB J. 2021 Jun;35(6):e21664.<br/>Free Radic Biol Med. 2022 Jun 22;S0891-5849(22)00463-4.<br/>Front Cell Dev Biol. 2021 Jun 21;9:671704.<br/>Front Cell Dev Biol. 2021 Sep 20;9:712224.<br/>Front Cell Dev Biol. 2023 May 10.<br/>Front Genet. 22 July 2022.<br/>Front Med. 2021 Sep 23;8:746298.<br/>Fundamental Research. 3 June 2022.<br/>Harvard Medical School LINCS LIBRARY<br/>Hepatology. 2022 Mar 27.<br/>Int J Biol Sci. 2021 Jun 26;17(11):2683-2702.<br/>Int J Biol Sci. 2023; 19(1): 204-224.<br/>Int J Mol Sci. 2022 Aug 12;23(16):9049.<br/>Int J Mol Sci. 2022, 23(14), 7586.<br/>Int J Mol Sci. 2022, 23(20), 12249.<br/>Int J Mol Sci. 2023 Mar 22;24(6):6008.<br/>Int J Mol Sci. 2023 Oct 31, 24(21), 15804.<br/>iScience. 2023 Jul 21.<br/>iScience. 6 October 2022, 105293.<br/>J Biol Chem. 2022: 102703.<br/>J Biol Chem. 2023 Dec 12:105556.<br/>J Biol Eng. 2024 Jan 16;18(1):7.<br/>J Cell Mol Med. 2019 Jul;23(7):4627-4639.<br/>J Cell Mol Med. 2021 Nov;25(22):10684-10697.<br/>J Cereb Blood Flow Metab. 2021 Dec 8;271678X211065391.<br/>J Exp Med. 2022 Nov 7;219(11):e20212405.<br/>J Hazard Mater. 2023 Oct 5, 459, 132225.<br/>J Int Med Res. 2021 Nov;49(11):3000605211055378.<br/>JCI Insight. 2022 Jun 14;e158428.<br/>Lab Invest. 2021 May 18.<br/>Life Sci Alliance. 2022 Apr 19;5(8):e202201421.<br/>Life Sci. 2020 Sep 1;256:117983.<br/>Materials Today Chemistry 12 (2019) 78e84<br/>Methods Mol Biol. 2022 Dec 15.<br/>Mil Med Res. 2020 Sep 6;7(1):42. <br/>Mol Cell. 2017 Mar 2;65(5):873-884.e8. <br/>Mol Cell. 2022 Jun 3;S1097-2765(22)00480-4.<br/>Mol Ther-Nucl Acids. 2021 May 28.<br/>Molecules. 2020 Apr 23;25(8):1980.<br/>Nat Chem Biol. 2020 Dec;16(12):1411-1419.<br/>Nat Commun. 2022 Sep 6;13(1):5237.<br/>Nat Genet. 2024 Feb;56(2):294-305.<br/>Nat Med. 2016 May;22(5):547-56. <br/>Nat Metab. 2023 Jun;5(6):1014-1028.<br/>Nucleic Acids Res. 2021 Nov 18;49(20):11575-11595.<br/>Nucleic Acids Res. 2022 Jul 1;gkac542.<br/>Oncol Lett. 2023 Aug 30.<br/>Oxid Med Cell Longev. 2020 Nov 26;2020:4830418.<br/>Patent. US20180263995A1.<br/>Patent. US20210002607A1.<br/>Pigment Cell Melanoma Res. 2023 Aug 9.<br/>PLoS Biol. 2019 Oct 15;17(10):e3000498.<br/>Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):4989-4998.<br/>Programa de Doctorado en Biomedicina. 2020 Sep.<br/>Res Sq. 2024 Jun 03.<br/>Res Sq. 2024 May 20.<br/>Research Square Preprint. 2021 Feb.<br/>Research Square Preprint. 2021 Nov.<br/>Respir Res. 2022 Mar 25;23(1):70.<br/>Rice University, Department of Biological Sciences. 2020 Apr.<br/>Ruperto Carola University Heidelberg. Faculty of Natural Sciences and Mathematics. 03 Mar 2022.<br/>Sci Adv. 2021 Apr 14;7(16):eabb2213.<br/>Sci Adv. 2023 Dec 22;9(51):eadi5683.<br/>Sci China Life Sci. 2018 Oct;61(10):1151-1167.<br/>Sci Rep. 2019 Dec 10;9(1):18731. <br/>Small. 2020 Jun;16(22):e2001371.<br/>SSRN. 2023 Sep 1.<br/>STAR Protoc. 17 June 2022, 101426.<br/>STAR Protoc. 2021 Nov 5;2(4):100881.<br/>STAR Protoc. 2023 Feb 3;4(1):102092.<br/>STAR Protoc. 2023 Mar 16;4(2):102151.<br/>Stem Cell Res Ther. 2021 Mar 29;12(1):214.<br/>Stem Cell Res Ther. 2022 Feb 2;13(1):48.<br/>Stem Cell Res Ther. 2023 Jan 5;14(1):1.<br/>Stem Cell Res Ther. 2020 Apr 16;11(1):157.<br/>Stem Cells Int. 2018 Dec 25;2018:5965727.<br/>Stem Cells Int. 2020 Feb 3;2020:8483035.<br/>Stem Cells Transl Med. 2021 May;10(5):743-755.<br/>Stem Cells. 2019 Apr;37(4):489-503.<br/>Stem Cells. 2022 Jul 28;sxac050.<br/>Theranostics. 2018 Jul 30;8(15):4262-4278.<br/>Theranostics. 2019 Aug 12;9(20):5769-5783.<br/>Toxicol Appl Pharmacol. 2020 Jan 1;386:114813.<br/>Toxicology. 2016 May 20;355-356:31-38. <br/>Toxicology. 2020 Apr 15;435:152422.<br/>Toxins. 2021 Aug 22;13(8):585.<br/>University of Otago. Biomedical Sciences. 2021 Nov.<br/>UNIVERSITY OF PAVIA. 2023 Jul 9.<br/>Zool Res. 2021 May 18;42(3):377-388.<br/>EMBO Mol Med. 2022 Nov 2;e16194.<br/>J Transl Med. 2021 Oct 9;19(1):417.<br/>[1]Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.<br/>[2]Bennett CN, et al. Regulation of Wnt signaling during adipogenesis. J Biol Chem. 2002 Aug 23;277(34):30998-1004.<br/>[3]Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors.BMC Res Notes. 2014 Apr 29;7:273.<br/>[4]Wang X, et al. Pharmacologically blocking p53-dependent apoptosis protects intestinal stem cells and mice from radiation. Sci Rep. 2015 Apr 10;5:8566.<br/>[5]Ye S, et al. Pleiotropy of glycogen synthase kinase-3 inhibition by CHIR99021 promotes self-renewal of embryonic stem cells from refractory mouse strains. PLoS One. 2012;7(4):e35892.
Smiles	N#CC1=CC=C(NCCNC2=NC=C(C3=NC=C(C)N3)C(C4=CC=C(Cl)C=C4Cl)=N2)N=C1.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CHIR-99021 (monohydrochloride); CT99021 (monohydrochloride)
Available
Product Description	Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy[1][2][3].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	501.80
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : 60 mg/mL (ultrasonic)\|H2O : 7.14 mg/mL (ultrasonic)
Target	Autophagy; GSK-3; Organoid; Wnt; β-catenin
Manufacturers Target	Autophagy; GSK-3; Organoid; Wnt; β-catenin
Isoform	GSK-3α; GSK-3β
Manufacturers Pathway	Autophagy; PI3K/Akt/mTOR; Stem Cell/Wnt
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10182A-100mg-safety-datasheet.pdf